BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12576447)

  • 1. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.
    Lancaster JM; Sayer R; Blanchette C; Calingaert B; Whitaker R; Schildkraut J; Marks J; Berchuck A
    Clin Cancer Res; 2003 Feb; 9(2):762-6. PubMed ID: 12576447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.
    Horak P; Pils D; Kaider A; Pinter A; Elandt K; Sax C; Zielinski CC; Horvat R; Zeillinger R; Reinthaller A; Krainer M
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8585-91. PubMed ID: 16361541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
    Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
    Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft.
    Huang X; Lin T; Gu J; Zhang L; Roth JA; Stephens LC; Yu Y; Liu J; Fang B
    Gene Ther; 2002 Oct; 9(20):1379-86. PubMed ID: 12365003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
    van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
    J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.
    Abdollahi T; Robertson NM; Abdollahi A; Litwack G
    Cancer Res; 2003 Aug; 63(15):4521-6. PubMed ID: 12907626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
    Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
    Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
    Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
    J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.
    Sayer RA; Lancaster JM; Pittman J; Gray J; Whitaker R; Marks JR; Berchuck A
    Gynecol Oncol; 2005 Feb; 96(2):355-61. PubMed ID: 15661221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The expression of TRAIL, TRAIL-R (DR4, DcR1) and Fas-L in patients with ovarian cancer].
    Li CM; Peng ZL; Yang KX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May; 36(3):341-3. PubMed ID: 15931863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions.
    Begue B; Wajant H; Bambou JC; Dubuquoy L; Siegmund D; Beaulieu JF; Canioni D; Berrebi D; Brousse N; Desreumaux P; Schmitz J; Lentze MJ; Goulet O; Cerf-Bensussan N; Ruemmele FM
    Gastroenterology; 2006 Jun; 130(7):1962-74. PubMed ID: 16762619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
    Runnebaum IB; Brüning A
    Clin Cancer Res; 2005 Sep; 11(17):6325-32. PubMed ID: 16144937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
    Tomek S; Horak P; Pribill I; Haller G; Rössler M; Zielinski CC; Pils D; Krainer M
    Gynecol Oncol; 2004 Jul; 94(1):107-14. PubMed ID: 15262127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis.
    Michowitz Y; Goldstein E; Roth A; Afek A; Abashidze A; Ben Gal Y; Keren G; George J
    J Am Coll Cardiol; 2005 Apr; 45(7):1018-24. PubMed ID: 15808757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene.
    Huang X; Lin T; Gu J; Zhang L; Roth JA; Liu J; Fang B
    Int J Oncol; 2003 Jun; 22(6):1241-5. PubMed ID: 12738989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
    Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
    Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
    Yamamoto T; Nagano H; Sakon M; Wada H; Eguchi H; Kondo M; Damdinsuren B; Ota H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Dono K; Umeshita K; Nakamori S; Yagita H; Monden M
    Clin Cancer Res; 2004 Dec; 10(23):7884-95. PubMed ID: 15585621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X; Kandasamy K; Srivastava RK
    Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.